Viatris has agreed to buy pain-drug maker Pacira BioSciences for $1.65 billion in a deal that expands the healthcare company's medicines portfolio.
The acquisition marks a significant move for Viatris as it seeks to broaden the range of products it offers. Pacira BioSciences is known for its pain-management medicines, and the transaction would bring that line of treatments under the Viatris umbrella.
The $1.65 billion price tag reflects the value the buyer places on Pacira's product lineup and its place in the market for pain relief. The deal is the latest in a series of portfolio-building moves in the healthcare sector, where companies often pursue acquisitions to strengthen their offerings and reduce reliance on any single product.
For Viatris, the agreement represents an effort to add growth opportunities through established medicines. For Pacira shareholders, the deal offers a premium exit for a company focused on pain treatment. Further details on closing timelines and regulatory review were not included in the original report.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing